Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Monday 29 June 2026 (5)
  • Until platform closure (16)
Poster categories
  • Thematic Poster Session (22)
keywords
Session Reference
  • L-TPS01 (12)
  • L-TPS02 (14)
  • L-TPS03 (10)
  • L-TPS04 (13)
  • L-TPS05 (10)
  • x L-TPS06 (8)
  • L-TPS07 (14)
  • L-TPS08 (9)
  • L-TPS09 (13)
  • L-TPS10 (14)
  • L-TPS11 (15)
  • L-TPS12 (11)
  • L-TPS13 (12)
  • L-TPS14 (14)
  • L-TPS15 (12)
  • L-TPS16 (9)
  • L-TPS17 (13)
  • L-TPS18 (13)
  • L-TPS19 (9)
  • L-TPS20 (14)
  • L-TPS21 (8)
  • L-TPS22 (10)
  • L-TPS23 (14)
  • L-TPS24 (14)
  • L-TPS25 (5)
  • TPS01 (14)
  • TPS02 (12)
  • TPS03 (10)
  • TPS04 (12)
  • TPS05 (13)
  • x TPS06 (14)
  • TPS07 (9)
  • TPS08 (15)
  • TPS09 (14)
  • TPS10 (11)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (9)
  • TPS16 (12)
  • TPS17 (12)
  • TPS18 (11)
  • TPS19 (11)
  • TPS20 (13)
  • TPS21 (14)
  • TPS22 (11)
  • TPS23 (11)
  • TPS24 (12)
  • TPS25 (8)
  • TPS26 (16)
  • TPS27 (13)
  • TPS28 (5)
  • TPS29 (6)
  • TPS30 (12)
  • TPS31 (10)
  • TPS32 (12)
  • TPS33 (14)
  • TPS34 (15)
  • TPS35 (11)
  • TPS36 (11)
  • TPS37 (12)
  • TPS38 (12)
  • TPS39 (13)
  • TPS40 (10)
  • TPS41 (14)
  • TPS42 (15)
  • TPS43 (15)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (11)
  • TPS47 (14)
  • TPS48 (11)
  • TPS49 (12)
  • TPS50 (9)
  • TPS51 (8)
  • TPS52 (14)
  • TPS53 (12)
  • TPS54 (11)
  • TPS55 (13)
  • TPS56 (13)
  • TPS57 (5)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (12)
  • TPS61 (12)
  • TPS62 (13)
  • TPS63 (12)
  • TPS64 (15)
  • TPS65 (14)
  • TPS66 (13)
  • TPS67 (13)
  • TPS68 (11)
  • TPS69 (15)
  • TPS70 (13)
  • TPS71 (9)
  • TPS72 (13)
  • TPS73 (12)
  • TPS74 (10)
  • TPS75 (13)
  • TPS76 (10)
  • TPS77 (7)
  • TPS78 (14)
  • TPS79 (13)
  • TPS80 (11)
  • TPS81 (6)
  • TPS82 (12)
  • TPS83 (6)
  • TPS84 (11)
  • TPS85 (11)
  • TPS86 (13)
  • TPS87 (10)
  • TPS88 (9)
  • TPS89 (7)
  • TPS90 (5)
  • TPS91 (5)
22 results
Thumbnail

D1.396 - Drug hypersensitivity reactions in paediatric patients pre and post-liver transplant: a single-center study

Thumbnail

D1.394 - Functional AOC1 variants associated with reduced diamine oxidase activity mimicking multiple drug hypersensitivity and mast cell disorders

Thumbnail

D1.397 - Successfull rapid drug desensitization to cemiplimab in a patient with lung squamous cell carcinoma

Thumbnail

D1.398 - Safety Outcomes and Predictors of Clinically Significant Reactions in Positive Drug Provocation Tests: A 10-Year Tertiary-Center Cohort

Thumbnail

D1.399 - Selective IgE Mediated Anaphylaxis to Gadobutrol and type I Kounis with tolerance to Gadoxetate Disodium

Thumbnail

D1.400 - Omalizumab premedication improves ferric carboxymaltose desensitization outcomes: A Case Report

Thumbnail

D1.401 - Progression from Immediate to Delayed Hypersensitivity: A Rare Case of Iodixanol-Induced Acute Generalised Exanthematous Pustulosis

Thumbnail

D1.402 - Angiotensin-Converting Enzyme Inhibitor–Induced Bradykinin-Mediated Angioedema: Three Cases of Sustained Remission Following Definitive Discontinuation and the Critical Role of the Prescribing Physician

Thumbnail

D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma

Thumbnail

D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report

Thumbnail

D1.108 - Optimization of phenotyping in severe T2-bronchial asthma

Thumbnail

D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy

Thumbnail

D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients

Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study

Thumbnail

D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study

Thumbnail

D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study

Thumbnail

D1.114 - Efficacy of Radical Endoscopic Surgery Combined with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps Complicated with Bronchial Asthma: A Real-World research

Thumbnail

D1.115 - Real World Assessment of Uncontrolled Severe Asthma in Canada - A Multi-Site Qualitative Survey of Type 2 Inflammatory Biomarkers and Clinical Outcomes

Thumbnail

D1.119 - Care pathways and systemic steroid (over)use in chronic rhinosinusitis with nasal polyps (CRSwNP) in Germany

Thumbnail

D1.120 - Genetic Associations with Asthma in the Kazakh Population: A Case–Control Study

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM